trihexyphenidyl 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
vasodilators	2745	144-11-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: trihexyphenidyl trihexyphenidyl hydrochloride benzhexol benzhexol hydrochloride trihexyphenidyl HCl benzhexol HCl	One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic. Molecular weight: 301.47 Formula: C20H31NO CLOGP: 5.15 LIPINSKI: 1 HAC: 2 HDO: 1 TPSA: 23.47 ALOGS: -4.98 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

trihexyphenidyl
trihexyphenidyl hydrochloride
benzhexol
benzhexol hydrochloride
trihexyphenidyl HCl
benzhexol HCl

One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.

Molecular weight: 301.47
Formula: C20H31NO
CLOGP: 5.15
LIPINSKI: 1
HAC: 2
HDO: 1
TPSA: 23.47
ALOGS: -4.98
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
10	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	10 mg/mL	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.63 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	99 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
May 13, 1949	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Dystonia	101.18	26.66	35	3336	13784	63471867
Dyskinesia	88.27	26.66	40	3331	31962	63453689
Coma	77.28	26.66	46	3325	64318	63421333
Extrapyramidal disorder	64.99	26.66	25	3346	13259	63472392
Parkinsonism	59.61	26.66	22	3349	10417	63475234
Muscle rigidity	57.53	26.66	22	3349	11478	63474173
Myoclonus	53.97	26.66	23	3348	15845	63469806
Drug interaction	53.16	26.66	63	3308	229068	63256583
Neuroleptic malignant syndrome	53.01	26.66	21	3350	12035	63473616
Tardive dyskinesia	48.84	26.66	18	3353	8484	63477167
Somnolence	47.95	26.66	53	3318	178632	63307019
Apraxia	45.97	26.66	12	3359	1809	63483842
Hyperchloraemia	45.14	26.66	10	3361	753	63484898
Tremor	43.98	26.66	44	3327	132195	63353456
Hypernatraemia	43.30	26.66	16	3355	7593	63478058
Hyperreflexia	43.29	26.66	15	3356	5919	63479732
Perseveration	42.47	26.66	8	3363	267	63485384
Urinary retention	39.86	26.66	23	3348	30278	63455373
Suicide attempt	37.94	26.66	29	3342	60889	63424762
Transient aphasia	33.35	26.66	5	3366	39	63485612
Intentional overdose	32.94	26.66	29	3342	74123	63411528
Onychophagia	30.55	26.66	5	3366	72	63485579
Disorientation	29.56	26.66	21	3350	39431	63446220
Hallucination, auditory	29.04	26.66	14	3357	12810	63472841
Drug screen false positive	28.09	26.66	7	3364	877	63484774
Electrocardiogram QT prolonged	27.88	26.66	24	3347	59506	63426145
Oculogyric crisis	27.88	26.66	8	3363	1713	63483938
Hallucination	27.52	26.66	23	3348	54794	63430857
Mental disorder	27.15	26.66	17	3354	25902	63459749
Ataxia	26.79	26.66	14	3357	15181	63470470

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Neuroleptic malignant syndrome	120.68	24.10	57	5124	17877	34933873
Coma	119.91	24.10	78	5103	45600	34906150
Wrong patient received product	118.12	24.10	34	5147	2620	34949130
Cerebral artery thrombosis	93.63	24.10	22	5159	758	34950992
Brain scan abnormal	90.99	24.10	22	5159	858	34950892
Hallucination	90.91	24.10	69	5112	51429	34900321
Extrapyramidal disorder	89.89	24.10	42	5139	12838	34938912
Failure to suspend medication	77.75	24.10	17	5164	421	34951329
Dystonia	77.64	24.10	36	5145	10809	34940941
Areflexia	68.02	24.10	23	5158	3008	34948742
Somnolence	66.52	24.10	82	5099	111034	34840716
Tardive dyskinesia	60.21	24.10	25	5156	5765	34945985
Respiratory distress	56.81	24.10	45	5136	35620	34916130
Parkinsonism	49.03	24.10	24	5157	8114	34943636
Accidental death	48.74	24.10	17	5164	2439	34949311
Pneumonia aspiration	42.71	24.10	41	5140	41862	34909888
Rhabdomyolysis	41.84	24.10	51	5130	68112	34883638
Hemiplegia	40.33	24.10	20	5161	6952	34944798
Cerebral amyloid angiopathy	39.55	24.10	8	5173	134	34951616
Dyskinesia	37.22	24.10	29	5152	22384	34929366
Disease recurrence	36.11	24.10	28	5153	21462	34930288
Facial paralysis	34.81	24.10	21	5160	10713	34941037
Ischaemic stroke	33.35	24.10	25	5156	18225	34933525
Toxicity to various agents	33.33	24.10	84	5097	200278	34751472
Drug abuse	32.47	24.10	55	5126	99041	34852709
Miosis	31.82	24.10	19	5162	9516	34942234
Salivary gland cancer stage IV	28.82	24.10	5	5176	34	34951716
Antipsychotic drug level increased	28.18	24.10	13	5168	3852	34947898
Spleen congestion	28.12	24.10	7	5174	308	34951442
Neutrophil count increased	28.06	24.10	22	5159	17124	34934626
Catatonia	27.83	24.10	14	5167	5011	34946739
Prothrombin level decreased	27.05	24.10	9	5172	1119	34950631
Faecaloma	26.94	24.10	14	5167	5363	34946387
Delusion	26.93	24.10	19	5162	12616	34939134
Bezoar	26.82	24.10	9	5172	1148	34950602
Akathisia	26.64	24.10	16	5165	8093	34943657
Compulsive shopping	26.39	24.10	7	5174	397	34951353
Delirium	25.49	24.10	32	5149	43959	34907791
Portal tract inflammation	25.17	24.10	5	5176	76	34951674
Psychotic disorder	25.04	24.10	24	5157	24428	34927322
Unmasking of previously unidentified disease	24.77	24.10	8	5173	906	34950844
Sexually inappropriate behaviour	24.75	24.10	7	5174	505	34951245
Dysarthria	24.59	24.10	28	5153	34754	34916996

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Coma	188.47	21.24	121	8017	100528	79635722
Neuroleptic malignant syndrome	167.83	21.24	73	8065	27486	79708764
Dystonia	164.83	21.24	67	8071	21332	79714918
Extrapyramidal disorder	154.35	21.24	65	8073	22614	79713636
Dyskinesia	115.04	21.24	66	8072	44707	79691543
Parkinsonism	107.73	21.24	46	8092	16538	79719712
Tardive dyskinesia	98.51	21.24	38	8100	10533	79725717
Hallucination	97.31	21.24	76	8062	85669	79650581
Somnolence	96.16	21.24	120	8018	238861	79497389
Wrong patient received product	86.89	21.24	28	8110	4590	79731660
Brain scan abnormal	86.79	21.24	21	8117	1202	79735048
Cerebral artery thrombosis	83.59	21.24	20	8118	1091	79735159
Failure to suspend medication	76.89	21.24	16	8122	458	79735792
Rhabdomyolysis	69.60	21.24	68	8070	103063	79633187
Muscle rigidity	66.77	21.24	35	8103	19847	79716403
Drug abuse	62.65	21.24	80	8058	162611	79573639
Pneumonia aspiration	60.49	21.24	52	8086	66915	79669335
Areflexia	59.17	21.24	22	8116	5512	79730738
Oculogyric crisis	55.94	21.24	18	8120	2934	79733316
Tremor	55.29	21.24	77	8061	170006	79566244
Respiratory distress	54.11	21.24	46	8092	58293	79677957
Drug interaction	53.03	21.24	125	8013	415058	79321192
Hypernatraemia	50.12	21.24	26	8112	14425	79721825
Suicide attempt	49.18	21.24	51	8087	82881	79653369
Catatonia	46.22	21.24	21	8117	8735	79727515
Salivary hypersecretion	44.81	21.24	24	8114	14200	79722050
Poisoning deliberate	43.69	21.24	26	8112	18802	79717448
Accidental death	42.03	21.24	16	8122	4275	79731975
Delirium	41.35	21.24	47	8091	84580	79651670
Psychotic disorder	41.18	21.24	34	8104	41368	79694882
Akathisia	40.73	21.24	22	8116	13237	79723013
Delusion	39.23	21.24	25	8113	20398	79715852
Hallucination, auditory	38.93	21.24	25	8113	20668	79715582
Disorientation	37.92	21.24	39	8099	62737	79673513
Faecaloma	37.80	21.24	20	8118	11544	79724706
Antipsychotic drug level increased	36.95	21.24	16	8122	5941	79730309
Pain	36.82	21.24	13	8125	703789	79032461
Diarrhoea	35.79	21.24	23	8115	880466	78855784
Urinary retention	35.69	21.24	36	8102	56594	79679656
Cerebral amyloid angiopathy	35.40	21.24	8	8130	339	79735911
Neutrophil count increased	35.36	21.24	27	8111	29369	79706881
Hyperchloraemia	34.83	21.24	10	8128	1111	79735139
Myoclonus	34.59	21.24	26	8112	27634	79708616
Perseveration	34.33	21.24	8	8130	389	79735861
Apraxia	32.87	21.24	12	8126	2855	79733395
White blood cell count increased	32.37	21.24	39	8099	74594	79661656
Abnormal behaviour	32.30	21.24	28	8110	36393	79699857
Miosis	32.01	21.24	20	8118	15769	79720481
Hyperreflexia	31.73	21.24	16	8122	8369	79727881
Agitation	30.67	21.24	44	8094	99671	79636579
Hemiplegia	30.48	21.24	19	8119	14920	79721330
Toxicity to various agents	30.17	21.24	103	8035	421437	79314813
Disease recurrence	29.56	21.24	29	8109	44080	79692170
Facial paralysis	29.03	21.24	21	8117	21051	79715199
Ischaemic stroke	28.43	21.24	25	8113	33106	79703144
Fatigue	28.35	21.24	32	8106	929695	78806555
Spleen congestion	28.17	21.24	7	8131	447	79735803
Salivary gland cancer stage IV	27.62	21.24	5	8133	67	79736183
Hyperammonaemia	27.52	21.24	16	8122	11077	79725173
Schizophrenia	27.44	21.24	18	8120	15422	79720828
Prothrombin level decreased	27.01	21.24	9	8129	1635	79734615
Sexually inappropriate behaviour	26.91	21.24	7	8131	538	79735712
Hallucination, visual	26.70	21.24	24	8114	32705	79703545
Bezoar	26.24	21.24	10	8128	2678	79733572
Respiratory depression	26.04	21.24	22	8116	27608	79708642
Arthralgia	25.96	21.24	13	8125	571790	79164460
Sudden death	25.60	21.24	20	8118	22491	79713759
Dysarthria	25.58	21.24	33	8105	67589	79668661
Onychophagia	25.51	21.24	5	8133	105	79736145
Psychiatric symptom	25.38	21.24	13	8125	7022	79729228
Cognitive disorder	24.71	21.24	33	8105	69893	79666357
Portal tract inflammation	24.64	21.24	5	8133	126	79736124
Disturbance in attention	24.44	21.24	28	8110	50773	79685477
On and off phenomenon	24.43	21.24	10	8128	3230	79733020
Drug ineffective for unapproved indication	24.25	21.24	28	8110	51210	79685040
Bradykinesia	23.74	21.24	13	8125	8030	79728220
Ataxia	23.73	21.24	20	8118	25019	79711231
Persecutory delusion	23.49	21.24	11	8127	4898	79731352
Intentional overdose	23.19	21.24	40	8098	105920	79630330
Parkinsonian gait	23.07	21.24	7	8131	941	79735309
Confusional state	22.98	21.24	78	8060	317919	79418331
Psychomotor skills impaired	22.81	21.24	11	8127	5226	79731024
Headache	22.76	21.24	20	8118	653752	79082498
Labelled drug-disease interaction issue	22.58	21.24	4	8134	47	79736203
Altered state of consciousness	22.52	21.24	25	8113	43797	79692453
Impulse-control disorder	22.49	21.24	8	8130	1766	79734484
Electrocardiogram QT prolonged	22.29	21.24	36	8102	90350	79645900
Fanconi syndrome	22.17	21.24	9	8129	2847	79733403
Drug screen false positive	21.99	21.24	7	8131	1102	79735148
Pneumoconiosis	21.46	21.24	5	8133	243	79736007
Unmasking of previously unidentified disease	21.34	21.24	8	8130	2049	79734201
Macroprolactinaemia	21.28	21.24	3	8135	6	79736244
Choking	21.24	21.24	14	8124	12087	79724163

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N04AA01	NERVOUS SYSTEM ANTI-PARKINSON DRUGS ANTICHOLINERGIC AGENTS Tertiary amines
MeSH PA	D018726	Anti-Dyskinesia Agents
MeSH PA	D000978	Antiparkinson Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D018678	Cholinergic Agents
MeSH PA	D018680	Cholinergic Antagonists
MeSH PA	D018727	Muscarinic Antagonists
MeSH PA	D018377	Neurotransmitter Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Postencephalitic parkinsonism	indication	19972008	DOID:14332
Parkinsonism	indication	32798002
Parkinson's disease	indication	49049000	DOID:14330
Extrapyramidal disease	indication	76349003
Arteriosclerotic Parkinsonism	indication
Urinary tract obstruction	contraindication	7163005	DOID:5200
Chronic obstructive lung disease	contraindication	13645005	DOID:3083
Severe chronic ulcerative colitis	contraindication	14311001
Disorder of autonomic nervous system	contraindication	15241006
Toxic megacolon	contraindication	28536002	DOID:1770
Atony of colon	contraindication	29479008
Shigellosis	contraindication	36188001
Hypertensive disorder	contraindication	38341003	DOID:10763
Conduction disorder of the heart	contraindication	44808001
Low blood pressure	contraindication	45007003
Achalasia of esophagus	contraindication	45564002	DOID:9164
Chronic heart failure	contraindication	48447003
Dysuria	contraindication	49650001
Paralytic ileus	contraindication	55525008	DOID:8442
Ulcerative colitis	contraindication	64766004	DOID:8577
Hiatal hernia	contraindication	84089009	DOID:12642
Open-angle glaucoma	contraindication	84494001	DOID:1067
Kidney disease	contraindication	90708001	DOID:557
Thyrotoxicosis	contraindication	90739004	DOID:7997
Myasthenia gravis	contraindication	91637004	DOID:437
Tardive dyskinesia	contraindication	102449007
Dysentery	contraindication	111939009
Gastrointestinal obstruction	contraindication	126765001
Bleeding	contraindication	131148009
Gastroesophageal reflux disease	contraindication	235595009	DOID:8534
Disease of liver	contraindication	235856003	DOID:409
Benign prostatic hyperplasia	contraindication	266569009
Retention of urine	contraindication	267064002
Fever	contraindication	386661006
Angle-closure glaucoma	contraindication	392291006	DOID:13550
Pseudomembranous enterocolitis	contraindication	397683000
Gastric ulcer	contraindication	397825006	DOID:10808
Disorder of coronary artery	contraindication	414024009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.23	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Muscarinic acetylcholine receptor M1	GPCR	P11229	ACM1_HUMAN	ANTAGONIST	IC50	8.89	CHEMBL	CHEMBL
Muscarinic acetylcholine receptor M2	GPCR	P08172	ACM2_HUMAN		IC50	7.73	CHEMBL
Sigma non-opioid intracellular receptor 1	Membrane receptor	Q99720	SGMR1_HUMAN		Ki	7.35	DRUG MATRIX
Muscarinic acetylcholine receptor M4	GPCR	P08173	ACM4_HUMAN		IC50	8.17	CHEMBL
Muscarinic acetylcholine receptor M5	GPCR	P08912	ACM5_HUMAN		IC50	7.99	CHEMBL
Cytochrome P450 2D6	Enzyme	P10635	CP2D6_HUMAN		IC50	5.61	DRUG MATRIX
Muscarinic acetylcholine receptor M3	GPCR	P20309	ACM3_HUMAN		IC50	7.58	CHEMBL

External reference:

ID	Source
4019959	VUID
N0000148044	NUI
D00787	KEGG_DRUG
52-49-3	SECONDARY_CAS_RN
4017900	VANDF
4019959	VANDF
C0041009	UMLSCUI
CHEBI:9720	CHEBI
CHEMBL1490	ChEMBL_ID
DB00376	DRUGBANK_ID
CHEMBL1092	ChEMBL_ID
D014282	MESH_DESCRIPTOR_UI
5572	PUBCHEM_CID
7315	IUPHAR_LIGAND_ID
1318	INN_ID
6RC5V8B7PO	UNII
10811	RXNORM
2986	MMSL
5628	MMSL
d00970	MMSL
001641	NDDF
004664	NDDF
2190009	SNOMEDCT_US
387120000	SNOMEDCT_US
387336005	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Trihexyphenidyl Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0658	SOLUTION	2 mg	ORAL	ANDA	23 sections
Trihexyphenidyl Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0658	SOLUTION	2 mg	ORAL	ANDA	23 sections
Trihexyphenidyl Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0121-0658	SOLUTION	2 mg	ORAL	ANDA	23 sections
Trihexyphenidyl Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0591-5335	TABLET	2 mg	ORAL	ANDA	9 sections
Trihexyphenidyl Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0591-5337	TABLET	5 mg	ORAL	ANDA	9 sections
Trihexyphenidyl hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-0675	TABLET	2 mg	ORAL	ANDA	9 sections
Trihexyphenidyl hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	0615-0676	TABLET	5 mg	ORAL	ANDA	9 sections
Trihexyphenidyl Hydrochloride	Human Prescription Drug Label	1	16571-160	TABLET	2 mg	ORAL	ANDA	21 sections
Trihexyphenidyl Hydrochloride	Human Prescription Drug Label	1	16571-161	TABLET	5 mg	ORAL	ANDA	21 sections
Trihexyphenidyl Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	50090-2994	TABLET	2 mg	ORAL	ANDA	9 sections
TRIHEXYPHENIDYL HYDROCHLORIDE	Human Prescription Drug Label	1	50090-5205	TABLET	5 mg	ORAL	ANDA	10 sections
TRIHEXYPHENIDYL HYDROCHLORIDE	Human Prescription Drug Label	1	50090-5205	TABLET	5 mg	ORAL	ANDA	10 sections
TRIHEXYPHENIDYL HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51407-265	TABLET	2 mg	ORAL	ANDA	10 sections
TRIHEXYPHENIDYL HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51407-265	TABLET	2 mg	ORAL	ANDA	10 sections
TRIHEXYPHENIDYL HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51407-265	TABLET	2 mg	ORAL	ANDA	10 sections
TRIHEXYPHENIDYL HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51407-266	TABLET	5 mg	ORAL	ANDA	10 sections
TRIHEXYPHENIDYL HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51407-266	TABLET	5 mg	ORAL	ANDA	10 sections
TRIHEXYPHENIDYL HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	1	51407-266	TABLET	5 mg	ORAL	ANDA	10 sections
Trihexyphenidyl Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0633	TABLET	2 mg	ORAL	ANDA	10 sections
Trihexyphenidyl Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0634	TABLET	5 mg	ORAL	ANDA	10 sections
Trihexyphenidyl Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	53808-0696	TABLET	5 mg	ORAL	ANDA	9 sections
Trihexyphenidyl Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	54738-554	TABLET	2 mg	ORAL	ANDA	10 sections
Trihexyphenidyl Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	54738-555	TABLET	5 mg	ORAL	ANDA	10 sections
Trihexyphenidyl Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	61748-054	SYRUP	2 mg	ORAL	ANDA	21 sections
Trihexyphenidyl Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	61748-054	SYRUP	2 mg	ORAL	ANDA	21 sections
Trihexyphenidyl Hydrochloride	Human Prescription Drug Label	1	63850-0021	TABLET	2 mg	ORAL	ANDA	19 sections
Trihexyphenidyl Hydrochloride	Human Prescription Drug Label	1	63850-0022	TABLET	5 mg	ORAL	ANDA	19 sections
Trihexyphenidyl Hydrochloride	Human Prescription Drug Label	1	64725-0161	TABLET	5 mg	ORAL	ANDA	20 sections
Trihexyphenidyl Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	1	68151-2782	TABLET	2 mg	ORAL	ANDA	9 sections
Trihexyphenidyl Hydrochloride	Human Prescription Drug Label	1	69452-241	TABLET	2 mg	ORAL	ANDA	20 sections